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Summary Seventy-seven men with histologically proven and newly diagnosed prostate cancer were
investigated for the presence of bcl-2 protein overexpression and p53 protein accumulation by
immunohistochemistry. Forty-five men had evidence of locally advanced and metastatic disease and were
treated by means of hormone manipulation. Twenty-eight patients either failed to respond to initial hormone
manipulation or relapsed within 37 months from diagnosis (median 20 months). Of the 77 cancers, 37 (48%)
showed bcl-2 overexpression at diagnosis. Twenty-seven of those were treated with androgen ablation and 20
(74%) had hormone-refractory disease (P=0.0128). Twenty-three of 77 men (29.8%) had nuclear staining for
p53 protein. Twenty-one of those were treated with hormone manipulation and 14 (66.6%) showed hormone
resistance (P=0.0012). Seventeen patients had both bcl-2 overexpression and p53 protein accumulation, 16 of
whom were hormonally treated, with 13 (81.2%) having hormone-refractory disease (P<0.0001). These
findings suggest that the combined detection of p53 protein accumulation and bcl-2 overexpression may be
useful in predicting hormone resistance in prostate cancer. By deregulating programmed cell death, alterations
in these genes may prevent patients from responding to androgen ablation, or allow them to escape hormonal
control of the disease.
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Adenocarcinoma of the prostate is the third most common
malignancy in men in England and Wales, with over 8000
men dying from the disease every year (OPCS, 1993).
Prostate cancer is unpredictable in its clinical course and
biological behaviour. In Europe, over 50% of patients
present with locally advanced and/or metastatic disease,
amenable to palliation only. In these patients, androgen
ablation remains the treatment of choice. However,
approximately 15% of men will not respond to hormone
manipulation, and the majority of those who do respond
will relapse within 3 years. Hormone-refractory disease,
while remaining unpredictable, is an untreatable condition
resulting in considerable morbidity and mortality. Under-
standing the mechanisms by which a hormone-sensitive
tumour escapes control, and altering these mechanisms to
treat affected patients remains a challenge for clinicians and
scientists alike.
The accumulation of alterations to both cellular oncogenes
and tumour-suppressor genes (TSGs) is associated with
tumorigenesis (Bishop, 1991; Marshall, 1991). The biological
behaviour of a tumour and its response to treatment has been
shown to be associated with alteration in expression of these
oncogenes and TSGs.
In prostate cancer, it is now evident that hormone
manipulation achieves its effect through activation of
programmed cell death, otherwise known as apoptosis
(Kyprianou et al., 1990; Kerr, 1994; Colombel et al.,
1992). Apoptosis is a distinct mode of cell death, which
occurs in tissues under normal physiological conditions and
in disease, including cancer. A number of genes are
responsible for the regulation of apoptosis in disease and
in health, including the proto-oncogene bcl-2 (Hockenbury
et al., 1990; Bissonnette et al., 1992; Korsmeyer, 1992) and
the tumour-suppressor gene p53 (Lane, 1992; Shaw et al.,
1992). Bcl-2 is a protein which protects cells from going into
apoptosis. The encoded protein is expressed in the cytoplasm
of basal epithelial cells in normal and hyperplastic prostatic
tissue. It is also normally expressed in lymphocytes.
Hormone-refractory prostatic carcinomas characteristically
possess high levels of bcl-2 protein expressed diffusely
throughout the tumour. This is also seen in prostatic
intraepithelial neoplasia (Colombel et al., 1993). Bcl-2
overexpression appears to enable the prostate cancer cells
to survive in an androgen-deprived environment, and to
confer resistance to androgen withdrawal therapy. An
untreated prostatic carcinoma with a high proportion of
bcl-2-positive cells may, therefore, possess an inherent ability
to become hormone refractory as these cells are protected
from apoptosis following androgen ablation.
Nuclear accumulation of p53 protein has been shown to
be strongly associated with p53 mutations. Wild-type p53 is
involved in regulation of cellular proliferation by inducing
apoptosis in response to DNA damage, whereas p53 in its
mutant form is not able to mediate this effect. A significant
proportion of primary human prostatic carcinoma show
increased p53 nuclear protein accumulation, which appears to
correlate with androgen independence (Navone et al., 1993;
Aprikian et al., 1994).
Based on the evidence that bcl-2 and p53 serve,
respectively, a repressor and effector function of a common
cell death pathway, the aim of this study was to investigate
the combination of bcl-2 protein overexpression and p53
nuclear protein accumulation, and their significance in
relation to frequency of apoptotic bodies, tumour behaviour
and clinical outcome following treatment of various stages of
prostate cancer. The results and possible value of these two




Seventy-seven men with histologically proven and untreated
prostatic carcinoma were studied. Their age ranged from 46
to 88 years (median 71 years). Specimens were obtained from
transurethral resection specimens as well as trucut biopsies
before treatment. One sample was taken from a radical
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prostatectomy specimen. All tumours were clinically and
pathologically staged. Grading was performed using the
Gleason scoring system. All patients had serum prostate-
specific antigen (PSA) measurements before commencement
of treatment (Hybritech assay). Patients with advanced and/
or metastatic disease were treated by androgen ablation in
the form of bilateral orchidectomy or administration of a
luteinising hormone-releasing hormone (LHRH) analogue.
Men with apparently localised disease were treated by
watchful waiting, radical prostatectomy or external beam
irradiation. Untreated patients who progressed or those who
had radiation therapy and relapsed, received secondary
androgen ablation. The follow-up period ranged from 17 to
56 months (median 30 months). Failure to respond to
treatment was measured according to the following objective
and subjective criteria: (1) less than 50% reduction in serum
PSA levels measured at diagnosis; (2) lack of significant
alteration in tumour bulk and consistency by digital rectal
examination (DRE) and transrectal ultrasonography; and (3)
persistent or worsening symptoms directly related to prostate
cancer. Progression was defined by one or more of the
following observations: (1) a rising serum PSA by at least
50% after initial reduction; (2) new skeletal pain related to
metastases as shown by isotope bone scanning; and (3)
significant alteration in the primary tumour on DRE.
Immunohistochemistry andfrequency of apoptotic bodies
Sections (4 gim) were cut from formalin-fixed paraffin-
embedded blocks. These were picked up on APES-coated
slides, and dried at 60°C for 1 h. Antigen retrieval was
carried out in an Energy Beam Sciences H2500 microwave
processor. Sections were heated to 95°C in 0.1 M citrate
buffer, pH 7.6, and held at this temperature for 20 min before
immunostaining. Endogenous peroxidase activity was
quenched by incubation in 3% hydrogen peroxidase for
10 min, while other non-specific activity was reduced by
incubation in normal goat serum for a further 10 min. A
standard streptavidin-biotin complex (DAKO Duet) method
was used with sections incubated in optimally diluted primary
antisera overnight at 4°C. Both primary antibodies were
supplied by DAKO. The anti-p53 DO-7 (Dako, UK Ltd) was
diluted to 1: 250 in Tris-buffered saline (TBS), and anti-bcl-2
(Dako, UK Ltd) diluted in 1:40 in TBS. About 1000 cells
were counted simultaneously by two observers (MCR and
IA) to detect p53 nuclear protein accumulation and bcl-2
protein overexpression. The intensity of nuclear p53 protein
accumulation was classified according to the percentage of
cells with strong nuclear staining: + =5-25%, + + =26-
75%, + + + = >75%. Intensity of cytoplasmic staining for
bcl-2 in tumour cells was categorised as + =focal areas of
strong staining (<5%); + + =diffuse staining (5-50%);
+ + + =diffuse staining (>50%). Positive controls match-
ing the fixation protocol of the test material were used. These
were colorectal carcinoma for p53 and tonsil for bcl-2. In
addition, basal cells in benign prostatic glands and
lymphocytes, which are known to stain positively for bcl-2,
were used as internal positive control. Negative controls were
performed by omiting the primary antibody in each case.
Representative sections from 51 cancer specimens and ten
BPH tissue samples were analysed for frequency of apoptotic
bodies. For each case, a single representative slide
(haematoxylin and eosin stained) was chosen for grading
and counting of apoptotic bodies by two observers (MCR
and NMW). Apoptotic bodies were defined according to
established criteria (Searle et al., 1982). Areas of well-
preserved tumour corresponding to positive staining for p53
and/or bcl-2 were assessed. An eyepiece graticule was used to
define the area selected for counting. All interphase tumour
nuclei and apoptotic bodies in the field were counted. The
Figure 1 (a) Photomicrograph of a tissue section showing prostatic adenocarcinoma with strong nuclear staining (+ + +) for p53
(magnification approximately x 125). (b) Photomicrograph of a tissue section showing prostatic adenocarcinoma with positive
cytoplasmic staining for bcl-2 (magnification approximately x400).bcl-2 and p53 expression in hormone-refractory prostate cancer
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process was repeated until a total of 2000 interphase nuclei
were counted. The number of apoptotic bodies detected was
divided by 2 to give an apoptotic index (number of apoptotic
bodies per 1000 interphase nuclei). Fisher's exact test and
Kendall rank correlation were used for statistical analysis of




Forty-five patients (58.4%) had metastatic disease confirmed
by isotope bone scanning, and were treated by means of
hormone manipulation. Fourteen men had locally advanced
disease with no evidence of metastasis and 11 were treated
with external beam irradiation. The other three patients
received watchful waiting. Eighteen patients had clinically
localised disease. Of those, one had a radical prostatectomy
(T2aNOMO, Gleason score 5, negative margins and no
extracapsular extension), seven received radiotherapy, and
the remaining ten were observed.
Six of the 45 men treated by means of hormone
manipulation (13.3%) failed to respond to androgen
ablation, and died within 6 months from diagnosis. Of the
remaining 39 patients, 20 (51.3%) relapsed within 37 months
from the start of treatment (median 20 months). Seven of 18
patients treated by means of radiotherapy relapsed within 22
months from treatment (median 13 months), and were treated
by means of secondary androgen ablation. Of those, two men
failed to respond. Of the 13 patients on watchful waiting, two
died of disease progression and four from other unrelated
causes. The remaining seven men are alive and well. The
patient who had a radical prostatectomy is alive, well and
disease free with an undetectable serum PSA 56 months
following surgery.
Immunostaining and apoptotic index (AI)
Thirty-seven of the 77 cancers (48%) showed cytoplasmic
staining for bcl-2 (Figure Ib) (+, n= 17; + +, n= 14; + + +,
n =6). Twenty-seven of these 37 patients were treated with
hormone manipulation and 20 (74%) showed hormone
resistance (P=0.0128), either initially (n=5) or through
escape (n= 15). Twenty-three of 77 men (29.8%) showed
strong nuclear staining for p53 (Figure la) (+, n=3; + +,
n=1l; +++, n=9). Of those, 21 were treated with
hormones and 14 (66.6%) were hormone resistant
(P=0.0012) initially (n=4), or showed progression (n=12).
Seventeen patients showed both bcl-2 overexpression and p53
nuclear accumulation, 16 of whom were hormonally
manipulated, with 13 (81.3%) having hormone-resistant
disease (P<0.0001), at the onset of treatment (n=4), or by
relapse (n=9). Figures 2-4 illustrate the distribution of bcl-
2/p53 immunostaining in patients undergoing hormonal
therapy and their response to treatment. There were no
statistically significant differences between different groups of
patients who expressed bcl-2 and/or p53 in terms of serum
PSA, Gleason scores, tumour stage and response to radio-
therapy (data not shown). In the 51 cancer patients assessed
for frequency of apoptotic bodies, Al ranged from 0.5 to 24.5
(mean 2.1) and showed a statistically significant correlation
with high tumour grade (P<0.001). In men with BPH, Al
ranged from 0-0.5 (mean 0.3). There was no significant
correlation between Al and immunostaining for either p53
and/or bcl-2 proteins.
Discussion
p53 protein accumulation and bcl-2 overexpression have been
investigated independently in a large number of different
malignancies. In prostate cancer, p53 nuclear staining
appears to be present in approximately 20% of tumours
(Navone et al., 1993; Visakorpi et al., 1992; Mellon et al.,
1992) with occasional discrepancies, often attributed to
differences in antibodies used, the dilutions of these
antibodies, fixation and processing of the tissues, stage and
grade of the tumours investigated and finally, interpretation
of the staining patterns (Fisher et al., 1994). Several reports
also confirm that nuclear p53 accumulation correlates with
hormone-resistant and aggressive disease (Navone et al.,
1993; Hamdy et al., 1993; Aprikian et al., 1994; Myers et al.,
1994). Two further developments have heightened the interest
in p53 and its relationship with aggressive prostate cancer.
Firstly, the regulating effect of wild-type p53 on apoptosis,
and secondly, the finding that tumour regression in prostate
cancer following hormone manipulation is largely mediated
by programmed cell death (Kyprianou et al., 1990). This led
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Figure 2 bcl-2 expression and response to treatment following
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Figure 3 p53 nuclear protein accumulation and response to
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FIgure 4 Combined bcl-2 p53 staining and response to treatment
following hormone manipulation (n =45).
researchers to investigate other possible mechanisms by which
apoptosis could be deregulated in prostate cancer. resulting in
progression and hormonal escape. which to date. is an
incurable condition.
bcl-2 is an oncogene that prolongs cell viability by
preventing and overriding programmed cell death mechan-
isms. bcl-2 overexpression has been demonstrated in
hormone-independent prostate cancer in a number of
studies. In particular. McDonnell et al. (1992) have found a
strong correlation between bcl-2 overexpression by immuno-
histochemistry and progression of prostate cancer from
androgen dependence to hormone resistance in humans. A
more recent study by Raffo et al. (1995) demonstrated that
bcl-2 overexpression protected prostate cancer cell lines
(LNCaP) against apoptotic stimuli in vitro. and enabled the
cells to form tumours in castrated male nude mice in vivo.
supporting the hypothesis that bcl-2 may be an important
factor in the development of hormone-resistant disease. In
contrast with prostate cancer, several studies of bcl-2 in other
malignancies including colorectal. breast and lung cancer
have shown a correlation between bcl-2 protein expression
and favourable outcome (Ofner et al.. 1995: Pezzella et al..
1993: Leek et al.. 1994). There is. however. a growing body of
evidence linking bcl-2 and p53 interaction with regulation of
a common cell death pathway. Observations have been made
that bcl-2 is able to block p53-associated apoptosis in
transformed cell lines. In high-grade B lymphomas Pin's et
al. (1994) have demonstrated that simultaneous expression of
bcl-2 and p53 protein was associated with poorer prognosis
than p53 accumulation alone. Manrn et al. (1994) also found
that bcl-2 and p53 may act as potential regulators of a
common apoptotic pathway in lymphomagenesis. and
demonstrated that overexpressed bcl-2 suppressed wild-type
p53-associated apoptosis folloWing ;-irradiation. Further-
more. Haldar et al. (1994) have demonstrated a possible
novel mechanism for p53-induced apoptosis through down-
regulation of bcl-2. In prostate cancer. the relevance of this
phenomenon remains controversial. A recent report by
Berges et al. (1993) suggests that p53 gene expression is not
required to mediate programmed cell death in androgen-
deprived prostatic glandular epithelial cells. and a further
study showed that in rat androgen-sensitive prostatic
adenocarcinoma. the biochemical cascade leading to apopto-
sis was not activated by androgen withdrawal. as in the
ventral prostate (Branstr6m et al.. 1994).
This information has prompted us to investigate p53
protein accumulation and bcl-2 overexpression simulta-
neously in a series of patients with different stages of
untreated prostate cancer. and to correlate immunohisto-
chemical findings With frequency of apoptotic bodies and
clinical data collected from each patient. including response
to treatment. Our results show that approximately 50% of
primary prostatic tumours overexpress bcl-2. in accordance
with previous studies. but a higher percentage of tumours
(30%) were found to stain positively for nuclear p53
compared with the majority of other published series
including a previous study from our own institutions
(Mellon et al.. 1993: Hamdy et al.. 1993). This may reflect
differences in technique and the recent adoption of antigen
retrieval methods in our pathologyy departments. It is also
important to note that the antibody used has the abilitv to
detect both wild and mutant forms of p53. which is a known
limitation of immunohistochemical studies (Wynford -
Thomas. 1992: Hall and Lane. 1994). We have not
attempted to use other antibodies to detect p53 protein, in
view of recent evidence suggesting that D07 is the most
sensitive and specific currently available antibody when
correlated with p53 mutations (Baas et al.. 1994). In
accordance with previous work, frequency of apoptotic
bodies correlated significantly with high tumour grade
(Aihara et al.. 1994). but did not appear to be altered by
the presence or absence of p53 and or bcl-2 immunostaining.
However, the tissue samples analysed in our study were
obtained from newly diagnosed and untreated patients, which
may explain the lack of correlation with bcl-2 overexpression
and p53 protein accumulation. We have not been able to
collect tissue from hormonally treated men for ethical
reasons. It is this specific group of men. in particular those
with clinical signs of hormonal resistance or escape. who may
show alterations of apoptotic index in relation to their bcl-2
p53 immunohistochemical status. This putative correlation
has yet to be proven. When analysed individually, both p53
and bcl-2 overexpression appear to correlate independently
with hormone-resistant disease. When combined, this effect
appears to be synergistic. illustrated by the fact that over
80% of patients showed hormonal resistance and or escape
with high statistical significance.
Fifty years after the work of Charles Huggins (Huggins
and Hodges. 1941). the mechanisms of hormone resistance in
prostate cancer are still poorly understood. Our study has
attempted to shed some light on this phenomenon. Despite
the many unexplained complexities relating immunostaiing
with genetic alterations, our results suggest that the combined
detection of p53 protein accumulation and bcl-2 over-
expression may be useful in the prediction of hormone-
resistant disease in prostate cancer. Ongoing studies at the
molecular level may clarify some of the mechanisms
controlling hormone dependence of this common. vet
unpredictable. malignancy.
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